Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD

James O Burton; David J Goldsmith; Nicki Ruddock; Rukshana Shroff; Mandy Wan

doi:10.1186/s12882-018-1037-8

Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD

BMC Nephrol. 2018 Sep 20;19(1):240. doi: 10.1186/s12882-018-1037-8.

Authors

James O Burton^{1

2}, David J Goldsmith³, Nicki Ruddock⁴, Rukshana Shroff⁵, Mandy Wan⁶

Affiliations

¹ College of Life Sciences, University of Leicester, Leicester, UK. melanie.dillon@renalregistry.nhs.uk.
² University Hospitals of Leicester NHS Trust, Leicester, UK. melanie.dillon@renalregistry.nhs.uk.
³ Guy's and St. Thomas' NHS Trust, London, UK.
⁴ University Hospitals of Leicester NHS Trust, Leicester, UK.
⁵ Great Ormond Street Hospital for Children and University College London, London, UK.
⁶ Institute of Pharmaceutical Science, King's College, London, UK.

Abstract

This report comments on the relevance and utility of the recently published (2017) KDIGO Clinical Practice Guideline Update for the diagnosis, evaluation, prevention and treatment of mineral bone disease in patients with chronic kidney disease (CKD-MBD) with respect to UK clinical practice. This document replaces all previously published Renal Association guidelines on the topic.

Publication types

Review

MeSH terms

Chronic Kidney Disease-Mineral and Bone Disorder / diagnosis*
Chronic Kidney Disease-Mineral and Bone Disorder / epidemiology
Chronic Kidney Disease-Mineral and Bone Disorder / therapy*
Humans
Practice Guidelines as Topic / standards*
Randomized Controlled Trials as Topic / methods
Randomized Controlled Trials as Topic / standards
United Kingdom / epidemiology

Abstract

Publication types

MeSH terms

Grants and funding